MedTrace Logo

CYP2B6 Polymorphisms in Methadone Disposition

NCT01648283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-06-20

Study results available
· View outcomes & findings →

Summary

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes methadone.

Conditions

  • Healthy Volunteers

Interventions

DRUG

IV racemic methadone HCl

IV racemic Methadone HC1 6 mg

DRUG

Oral racemic methadone HCl

oral d5-methadone HCl 11 mg

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Evan Kharasch, MD, PhD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-03-31
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648283 on ClinicalTrials.gov